Film creditsWhere it goes changes what it means.
Distinguish surface deposition, retention within skin and permeation across skin before a cosmetic carrier acquires an overextended claim.
Proposed programme | Application, materials, capacity and rights to be qualified.
Delivery needs a destination.
The word delivery can mean deposition on a surface, association with a skin layer or passage into a receiver beyond the tissue.
The word delivery can mean deposition on a surface, association with a skin layer or passage into a receiver beyond the tissue. Those are different endpoints with different implications. A cosmetic formulation team should identify the intended function before adopting the most dramatic measurement or promotional phrase.
The proposed investigation asks where the compound needs to reside for the application question to be useful. A surface film may be the intended product behaviour; deeper permeation may be unnecessary or undesirable. The customer discussion would make the measured destination and the acceptable interpretation explicit, with clinical or treatment claims left outside this proposed programme.
Examine the development decision
Where it goes changes what it means.
Open the sequence to examine what a development decision needs.
Identify the exact preparation, its source, and the properties a second laboratory must be able to reproduce.
Explanatory geometry · no simulated or measured performance
A skin model is a chosen experiment.
OECD Test No.
OECD Test No. 428 describes an in vitro approach with skin separating donor and receiver compartments, alongside reporting of distributions and recovery (OECD, 2004). That framework underscores the importance of tissue source, preparation, exposure and analytical method. It does not approve a Bio protocol or establish a cosmetic efficacy result.
Zsikó et al. (2019) compared artificial and human-epidermis methods in a particular lidocaine carrier system. Agreement within that study cannot be treated as universal interchangeability. A new formulation requires a rationale for the model and an explanation of the decision it can support, including its limitations relative to the intended application.
Using transport equations within their boundary conditions.
The displayed permeability relation is a simplified planar diffusion model with partitioning at the donor–barrier boundary.
The displayed permeability relation is a simplified planar diffusion model with partitioning at the donor–barrier boundary. It assumes an appropriate homogeneous barrier description, constant properties and a justified receiver condition. It can explain why thickness, diffusion and partition all matter, but does not reproduce a complex biological barrier by itself.
A reader could inspect these dependencies without being offered a fictitious Bio skin prediction. Real finite dosing, depletion, layer structure and changing formulation activity can invalidate the simple expression. Any quantitative interpretation would need a qualified method and measured conditions, with the model’s usefulness assessed against the actual data and commercial question.
Illustrative barrier permeability; not a validated prediction for skin.
- permeability coefficientm s⁻¹
- effective diffusion coefficient in ideal barrierm² s⁻¹
- barrier-to-donor partition coefficient1
- uniform barrier thicknessm
Model conditions. Planar homogeneous barrier with constant properties. Appropriate boundary partitioning and steady diffusion; biological layering and finite dose omitted.
The carrier and its contribution.
Compare a structured carrier with a simpler vehicle around loading, availability, handling and the intended formulation.
Distinguish active movement from carrier movement.
A signal below a skin surface does not prove that an intact carrier reached the same location.
A signal below a skin surface does not prove that an intact carrier reached the same location. An active or label may have left the structure first. Luengo et al. (2021) investigated a local-pH explanation in a PLGA system, demonstrating why alternative mechanisms deserve deliberate controls.
The proposed study brief would avoid equating fluorescent intensity with intact-particle transport. Labels, free compound and carrier markers may need independent recovery or colocalisation methods when the mechanism matters. A simpler compound-distribution measurement may be sufficient for a formulation decision and more interpretable than an impressive image whose chemical specificity has not been established.
Reconstruct the dose, not only the receiver.
A meaningful compartment record includes material remaining on the surface, recovered from the barrier and appearing in the receiver, together with identified apparatus losses.
A meaningful compartment record includes material remaining on the surface, recovered from the barrier and appearing in the receiver, together with identified apparatus losses. Sampling and extraction need enough sensitivity for the expected distribution. An unclosed balance can conceal adsorption, degradation or incomplete recovery.
The OECD method’s reporting structure provides a useful basis for asking these questions (OECD, 2004). A Bio proposal would adapt the discussion to the qualified study purpose rather than presenting a public page as a ready protocol. Tissue access, ethics, method validation and regulatory expertise must be resolved before any such work is commissioned.
Defining the value for the formulation buyer.
A sponsor may want to choose between two vehicles, investigate retention at a relevant surface or identify whether increased receiver appearance is even desirable.
A sponsor may want to choose between two vehicles, investigate retention at a relevant surface or identify whether increased receiver appearance is even desirable. The commercial value is a decision tied to a specified endpoint. More uptake is not an automatic advantage and should not be sold as one.
The proposed paid output is an evidence-and-endpoint map with a comparator rationale and prospective study scope. It could support a qualified laboratory discussion, using materials and methods appropriate to the application. A later claim or licence would require the specific evidence and rights that justify it; an exploratory model or external paper does not provide those unlocks.
The application boundary.
Bring the intended product category, active identity, final base, acceptable exposure and incumbent.
Bring the intended product category, active identity, final base, acceptable exposure and incumbent. The opening decision is whether the question needs a deposition method, a surface-retention comparison or a qualified absorption investigation. Choosing that boundary early can save an elaborate experiment from answering the wrong commercial question.
A useful milestone is a reviewer-agreed endpoint and compartment plan, followed by a method that can recover the relevant fractions. If the intended benefit cannot be connected to a defensible measurement, the proposition should be narrowed. This page invites that scientific discussion while preserving the distinction between formulation research, finished-product claims and clinical development.
The next proposed comparison.
An endpoint-and-compartment map for a qualified non-clinical study discussion.
Colloidal delivery · Proposed development discussion
A development path
for this research.
Which measured compartment answers the intended cosmetic application without implying a clinical delivery result?
The people this could serve.Formulation, ingredient and application development teams.
The decision behind the project.
Your intended application, present alternative and the constraint behind “Skin barrier and delivery boundaries”. A useful starting point is the change that would justify another development step.
A proposed scope centred on an endpoint-and-compartment map for a qualified non-clinical study discussion.
Agree the comparison, acceptance basis and responsible expertise before discussing a paid package.
Specialist methods and a defined contribution.
Bring relevant analytical or experimental expertise, a comparator suggestion, and the conditions under which your method could resolve this question.
A jointly scoped proposal could connect your contribution with an endpoint-and-compartment map for a qualified non-clinical study discussion.
Define contributions, required access, independent preparations and permitted outputs before work or protected information is shared.
The commercial purpose of the next milestone.
Bring the application or asset thesis, the buyer you expect to value it, and the scientific or commercial uncertainty that must be resolved before another commitment.
The proposed decision record would connect the buyer question with an endpoint-and-compartment map for a qualified non-clinical study discussion. It would identify what a subsequent comparison needs to demonstrate.
Demand, development cost, resources, rights and a decision-changing milestone would need examination. No financing terms or investment outcome are represented here.
What a useful comparison
would record.
- Record permeability coefficient (m s⁻¹) with the preparation, method and conditions needed to interpret it.
- Record effective diffusion coefficient in ideal barrier (m² s⁻¹) with the preparation, method and conditions needed to interpret it.
- Record barrier-to-donor partition coefficient (1) with the preparation, method and conditions needed to interpret it.
What the proposed
brief could leave behind.
- An endpoint-and-compartment map for a qualified non-clinical study discussion
- A preparation, comparator and endpoint record tied to this question.
- A source-linked account of the evidence gaps, study assumptions and next review point.
The proposed discussion brief
A brief you
can take away.
Use non-confidential notes to connect this topic with your own decision. Entries stay in this browser tab; saving creates a text file on your device. Nothing is submitted.
Scoped paid evidence brief, then separately qualified comparison; evaluation or licensing only after reproducibility, capacity and rights review.
Notes are optional. The brief includes this page’s proposed question and public source links.
Proposed scope; resources, methods, rights and delivery terms would be agreed before work. Begin with non-confidential information.
Sources and reading notes.
External work is identified below. Access notes describe the material inspected for this page; company research questions and proposed work are not presented as findings from these sources.
OECD, 2004OECD (2004) Test No. 428: Skin Absorption: In Vitro Method
Dermal-absorption compartments, realistic exposure, temperature and recovery reporting.
Scope and limitations: General method, not Bio protocol approval or an efficacy/safety result. No PDF republication; tissue, ethics and legal requirements need qualified assessment.
Open original sourceZsikó et al, 2019Zsikó et al. (2019) Nanostructured Lipid Carrier Gel for the Dermal Application of Lidocaine: Comparison of Skin Penetration Testing Methods
NLC dispersion/gel, storage stability and method/membrane comparisons in a specific lidocaine system.
Scope and limitations: CC BY 4.0 full XML inspected. Pharmaceutical context; artificial-membrane agreement in this study does not establish cosmetic skin effects or universal equivalence.
Open original sourceLuengo et al, 2021Luengo et al. (2021) Human Skin Permeation Enhancement Using PLGA Nanoparticles Is Mediated by Local pH Changes
Carrier degradation, local pH, ionisation and controls in flufenamic-acid/caffeine skin experiments.
Scope and limitations: CC BY 4.0 full XML inspected. Specific acidic-drug study; no general particle passage, product efficacy or permission for Bio human-use work.
Open original source